Gilead Sciences, Inc. $GILD Position Reduced by Credit Agricole S A

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Credit Agricole S A lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 24.7% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 493,653 shares of the biopharmaceutical company's stock after selling 162,103 shares during the period. Credit Agricole S A's holdings in Gilead Sciences were worth $55,314,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in GILD. Redwood Financial Network Corp boosted its holdings in shares of Gilead Sciences by 4.0% in the 4th quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company's stock valued at $234,000 after purchasing an additional 98 shares during the last quarter. Argentarii LLC increased its holdings in shares of Gilead Sciences by 3.0% during the 1st quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company's stock worth $380,000 after buying an additional 99 shares during the last quarter. Peak Financial Advisors LLC raised its position in shares of Gilead Sciences by 1.7% in the 1st quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company's stock worth $677,000 after buying an additional 100 shares during the period. Perkins Coie Trust Co boosted its holdings in Gilead Sciences by 2.6% in the first quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company's stock valued at $435,000 after acquiring an additional 100 shares during the last quarter. Finally, Investment Research & Advisory Group Inc. boosted its holdings in Gilead Sciences by 33.3% in the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock valued at $45,000 after acquiring an additional 100 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $296,325.00. Following the transaction, the chief financial officer owned 160,110 shares in the company, valued at approximately $18,977,838.30. The trade was a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the transaction, the insider directly owned 114,168 shares of the company's stock, valued at $13,532,333.04. This represents a 19.70% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 82,000 shares of company stock worth $9,339,230. 0.27% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Oppenheimer dropped their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. Truist Financial upgraded Gilead Sciences from a "hold" rating to a "buy" rating and boosted their target price for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Morgan Stanley increased their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a research report on Friday, July 25th. Finally, Daiwa America upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday. Three research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $115.39.

Gilead Sciences Stock Down 2.2%

NASDAQ GILD traded down $2.59 on Thursday, reaching $116.14. The company had a trading volume of 6,062,069 shares, compared to its average volume of 6,678,418. The firm has a market capitalization of $144.11 billion, a PE ratio of 23.14, a P/E/G ratio of 0.73 and a beta of 0.33. Gilead Sciences, Inc. has a 1 year low of $75.35 and a 1 year high of $121.83. The firm has a 50-day moving average of $112.41 and a 200-day moving average of $108.90. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same quarter last year, the firm posted $2.01 earnings per share. The business's quarterly revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be issued a $0.79 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. Gilead Sciences's payout ratio is currently 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.